BREAKING: Today the first patient in Ver-A-T1D was successfully randomised in the Medizinische Universität Graz. This INNODIA trial has the objective of examining the protective function of Verapamil on the pancreas in adults who have recently been diagnosed with type 1 diabetes. Last Friday the team received the good news that the first screened patient fulfilled all criteria for inclusion in this intervention study. Meaning all 4 trials to slow down β cell destruction in the pancreas have officially started. INNODIA getting closer every day to prevent and stop T1D!
First patient in Ver-A-T1D successfully randomised
15. February 2021